Persistent corneal epithelial defect – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:16:38 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Persistent corneal epithelial defect – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-cenegermin-eye-drops-in-patients-with-persistent-corneal-epithelial-defect/ Fri, 08 May 2026 05:45:37 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-cenegermin-eye-drops-in-patients-with-persistent-corneal-epithelial-defect/ This clinical trial is being done in people with Persistent Corneal Epithelial Defect (PCED), a condition in which the clear front surface of the eye does not heal properly. The study is testing cenegermin eye drops, given as an eye solution, and comparing them with a vehicle eye drop solution. Before the study eye drops are given, other eye drops such as oxybuprocaine hydrochloride, tetracaine hydrochloride, and tropicamide may be used as part of the eye care routine. The purpose of the study is to see whether cenegermin can help the eye surface heal better than the vehicle.

People in the study are assigned by chance to one of the eye drop groups. The study lasts for several weeks, and the eye is checked during treatment and again afterward to see whether healing has been maintained. The main focus is whether the damaged eye surface closes and stays healed over time.

]]> Study on Insulin Eye Drops for Treating Persistent Corneal Epithelial Defect in Patients with Neurotrophic or Chronic Ocular Surface Diseases https://clinicaltrials.eu/trial/study-on-insulin-eye-drops-for-treating-persistent-corneal-epithelial-defect-in-patients-with-neurotrophic-or-chronic-ocular-surface-diseases/ Wed, 29 Apr 2026 14:58:10 +0000 https://clinicaltrials.eu/trial/study-on-insulin-eye-drops-for-treating-persistent-corneal-epithelial-defect-in-patients-with-neurotrophic-or-chronic-ocular-surface-diseases/ This clinical trial is focused on studying a condition known as persistent corneal epithelial defect. This condition affects the surface of the eye, where the outermost layer of the cornea does not heal properly. The study is testing the effectiveness and safety of using insulin eye drops as a treatment. Insulin, commonly known for its role in managing diabetes, is being explored here in a new form as eye drops to help heal the corneal surface.

The purpose of the study is to compare the insulin eye drops with the standard treatment, which involves using autologous serum eye drops. These are eye drops made from a patient’s own blood. The trial will observe how well the insulin eye drops work in healing the corneal defect, especially in cases where the defect is due to nerve damage or long-term eye surface diseases.

Participants in the study will receive either the insulin eye drops or the standard treatment. The study will monitor the healing process over a period of time to see if the corneal defect closes completely. The trial aims to determine how quickly the healing occurs and whether the insulin eye drops are as effective or more effective than the current standard treatment. The study will also look at other factors such as age, sex, and previous eye conditions to understand their impact on the treatment’s success.

]]> Study on the Safety and Effectiveness of Lufepirsen Gel for Patients with Persistent Corneal Epithelial Defects https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-lufepirsen-gel-for-patients-with-persistent-corneal-epithelial-defects/ Wed, 29 Apr 2026 14:30:29 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-lufepirsen-gel-for-patients-with-persistent-corneal-epithelial-defects/ This clinical trial is focused on studying a condition known as Persistent Corneal Epithelial Defects. This condition affects the clear, outer layer of the eye, known as the cornea, and involves a defect or wound that does not heal properly. The trial will evaluate a treatment called NEXAGON, which is an ophthalmic gel containing the active ingredient lufepirsen. The purpose of the study is to assess the safety and effectiveness of NEXAGON in helping the cornea heal and maintain its healing for at least 28 days.

Participants in the study will be randomly assigned to receive either the NEXAGON gel or a similar gel that does not contain the active ingredient, known as a placebo. The study will be conducted over a period of time, during which participants will apply the gel to their eyes as directed. Throughout the study, the healing of the corneal defect will be monitored using special imaging techniques to ensure accurate assessment.

The trial aims to determine if NEXAGON can successfully promote the healing of the corneal defect and maintain this healing over time. Participants will be closely monitored for any side effects or changes in their condition. The study will provide valuable information on the potential benefits of NEXAGON for individuals with persistent corneal epithelial defects.

]]>